Platelet VEGF and serum TGF-β1 levels predict chemotherapy response in non-small cell lung cancer patients

Tumor Biology

Volumn 36, Issue 8, 2015, Pages 6477-6483

  Fu, Bao Hong ^a   Fu, Zhan Zhao ^a   Meng, Wei ^b   Gu, Tao ^a   Sun, Xiao Dong ^c   Zhang, Zhi ^c  

^a First Hospital of Qinhuangdao City   (China)

^b HEBEI NORTH UNIVERSITY   (China)

^c Tangshan Workers Hospital   (China)

Author keywords

Chemotherapy; Clinical value; Disease activity; Enzyme linked immunosorbent assay; Non small cell lung cancer; Platelet vascular endothelial growth factor level; Transforming growth factor beta 1; Vascular endothelial growth factor

Indexed keywords

CISPLATIN; GEMCITABINE; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOCYTE COUNT; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; THROMBOCYTE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PLATELETS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84940436076     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3338-x     Document Type: Article

References (46)

1. National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. New Engl J Med. 2011;365(5):395–409.
2. Jia Y, Zang A, Shang Y, Yang H, Song Z, Wang Z, et al. Microrna-146a rs2910164 polymorphism is associated with susceptibility to non-small cell lung cancer in the chinese population. Med Oncol. 2014;31(10):194.
3. Wu H, Qiao N, Wang Y, Jiang M, Wang S, Wang C, et al. Association between the telomerase reverse transcriptase (tert) rs2736098 polymorphism and cancer risk: evidence from a case-control study of non-small-cell lung cancer and a meta-analysis. PLoS One. 2013;8(11):e76372.
4. Lopez-Cima MF, Garcia-Perez J, Perez-Gomez B, Aragones N, Lopez-Abente G, Tardon A, et al. Lung cancer risk and pollution in an industrial region of northern Spain: a hospital-based case-control study. Int J Health Geogr. 2011;10:10.
5. Xu J, Yin Z, Gao W, Liu L, Yin Y, Liu P, et al. Genetic variation in a microrna-502 minding site in set8 gene confers clinical outcome of non-small cell lung cancer in a chinese population. PLoS One. 2013;8(10):e77024.
6. Merrow CE, Wang IZ, Podgorsak MB. A dosimetric evaluation of VMAT for the treatment of non-small cell lung cancer. J Appl Clin Med Phys Am Coll Med Phys. 2013;14(1):4110.
7. Xu YH, Lu S. A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer. Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2014;40(3):311–7.
8. Tang S, Pan Y, Wang Y, Hu L, Cao S, Chu M, et al. Genome-wide association study of survival in early-stage non-small cell lung cancer. Ann Surg Oncol. 2015;22(2):630–5.
9. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94.
10. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605–44.
11. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175–80.
12. Albain KS, Swann RS, Rusch VW, Turrisi 3rd AT, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374(9687):379–86.
13. Aerts HJ, Bosmans G, van Baardwijk AA, Dekker AL, Oellers MC, Lambin P, et al. Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study. Int J Radiat Oncol Biol Phys. 2008;71(5):1402–7.
14. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, et al. Ephrin-b2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature. 2010;465(7297):483–6.
15. Rondina MT, Weyrich AS, Zimmerman GA. Platelets as cellular effectors of inflammation in vascular diseases. Circ Res. 2013;112(11):1506–19.
16. Semple JW, Italiano Jr JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11(4):264–74.
17. Bambace NM, Levis JE, Holmes CE. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets. 2010;21(2):85–93.
18. Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol. 2011;51(4):600–6.
19. Halwani R, Al-Muhsen S, Al-Jahdali H, Hamid Q. Role of transforming growth factor-beta in airway remodeling in asthma. Am J Respir Cell Mol Biol. 2011;44(2):127–33.
20. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A. 2011;108(9):3749–54.
21. Bierie B, Moses HL. Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev. 2010;21(1):49–59.
22. Foreword IF. Target therapy for cancer: anti-cancer drugs targeting growth-factor signaling molecules. Biol Pharm Bull. 2011;34(12):1773.
23. Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, Michallet AS, Warzocha K, Bilinski P, et al. Pretreatment levels of vascular endothelial growth factor in plasma predict a complete remission rate and time to relapse or progression in patients with diffuse large b-cell lymphoma. Arch Immunol Ther Exp. 2013;61(2):165–74.
24. Wang ST, Liu JJ, Wang CZ, Lin B, Hao YY, Wang YF, et al. Expression and correlation of Lewis y antigen and TGF-beta1 in ovarian epithelial carcinoma. Oncol Rep. 2012;27(4):1065–71.
25. Kim JW, Koh Y, Kim DW, Ahn YO, Kim TM, Han SW, et al. Clinical implications of VEGF, TGF-beta1, and IL-1beta in patients with advanced non-small cell lung cancer. Cancer Res Treat: Off J Korean Cancer Assoc. 2013;45(4):325–33.
26. Fu ZZ, Gu T, Fu BH, Hua HX, Yang S, Zhang YQ, et al. Relationship of serum levels of VEGF and TGF-beta1 with radiosensitivity of elderly patients with unresectable non-small cell lung cancer. Tumour Biol: J Int Soc Oncodev Biol Med. 2014;35(5):4785–9.
27. [the helsinki declaration of the world medical association (wma). Ethical principles of medical research involving human subjects]. Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego 2014;36(215):298-301.
28. Fu ZZ, Sun XD, Li P, Zhang Z, Li GZ, Gu T, et al. Relationship between serum VEGF level and radiosensitivity of patients with nonsmall cell lung cancer among Asians: a meta-analysis. DNA Cell Biol. 2014;33(7):426–37.
29. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised recist guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
30. Huang L, Jia J, Liu R. Decreased serum levels of the angiogenic factors VEGF and TGF-beta1 in Alzheimer’s disease and amnestic mild cognitive impairment. Neurosci Lett. 2013;550:60–3.
31. Xian LW, Li TP, Wei YE, Wu SP, Ma L. Relation of advanced oxidation protein products with VEGF and TGF-beta1 in colon cancer cells exposed to intermittent hypoxia. Nan fang yi ke da xue xue bao = J South Med Univ. 2011;31(4):619–23.
32. Seo HY, Park JM, Park KH, Kim SJ, Oh SC, Kim BS, et al. Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients. Jpn J Clin Oncol. 2010;40(12):1147–53.
33. Peterson JE, Zurakowski D, Italiano Jr JE, Michel LV, Connors S, Oenick M, et al. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis. 2012;15(2):265–73.
34. Koukourakis MI, Limberis V, Tentes I, Kontomanolis E, Kortsaris A, Sivridis E, et al. Serum VEGF levels and tissue activation of VEGFR2/KDR receptors in patients with breast and gynecologic cancer. Cytokine. 2011;53(3):370–5.
35. Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ, Tan MH, et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol: Off J Eur Soc Med Oncol ESMO. 2012;23(6):1549–55.
36. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2011;2(12):1097–105.
37. Takai E, Tsukimoto M, Kojima S. TGF-beta1 downregulates COX-2 expression leading to decrease of PGE2 production in human lung cancer A549 cells, which is involved in fibrotic response to TGF-beta1. PLoS One. 2013;8(10):e76346.
38. Mumm JB, Oft M. Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. Oncogene. 2008;27(45):5913–9.
39. Hou Y-L, Chen H, Dong Z-H, Xue C-J, Wu Y-F, Luo H-X, et al. Clinical significance of serum transforming growth factor-β1 in lung cancer. Cancer Epidemiol. 2013;37(5):750–3.
40. Kumar S, Guleria R, Singh V, Mohan A, Bharti AC, Das BC. Lack of utility of plasma TNF-alpha level in predicting therapeutic efficacy in patients with advanced non-small cell lung cancer. Cytokine. 2010;51(3):245–8.
41. Neil JR, Johnson KM, Nemenoff RA, Schiemann WP. Cox-2 inactivates smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis. 2008;29(11):2227–35.
42. Kumar S, Guleria R, Mohan A, Singh V, Bharti AC, Das BC. Efficacy of plasma TGF-beta1 level in predicting therapeutic efficacy and prognosis in patients with advanced non-small cell lung cancer. Cancer Investig. 2011;29(3):202–7.
43. Liu J, Liao S, Diop-Frimpong B, Chen W, Goel S, Naxerova K, et al. TGF-beta blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci U S A. 2012;109(41):16618–23.
44. Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica. 2011;96(9):1302–9.
45. Lim MJ, Lin T, Jakowlew SB. Signaling mechanisms of transforming growth factor-β (TGF-β) in cancer: TGF-β induces apoptosis in lung cells by a smad-dependent mechanism. Tumor Suppressor Genes 2012;145:123-125
46. Maitah MY, Ali S, Ahmad A, Gadgeel S, Sarkar FH. Up-regulation of sonic hedgehog contributes to TGF-beta1-induced epithelial to mesenchymal transition in NSCLC cells. PLoS One. 2011;6(1):e16068.